Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyproneâ„¢ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.
PR Newswire
MARLBOROUGH, Mass., April 4, 2018